2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Leukemia, Myeloid, Acute
151
Leukemia
67
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Leukemia, Myelomonocytic, Acute
26
Leukemia, Monocytic, Acute
26
Myelodysplastic Syndromes
24
Leukemia, Erythroblastic, Acute
23
Leukemia, Megakaryoblastic, Acute
22
Congenital Abnormalities
21
Leukemia, Promyelocytic, Acute
13
Leukemia, Myelomonocytic, Chronic
12
Anemia, Refractory, with Excess of Blasts
12
Recurrence
8
Myeloproliferative Disorders
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma
7
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Eosinophilic, Acute
7
Leukemia, Biphenotypic, Acute
7
Carcinoma, Hepatocellular
7
Leukemia, Basophilic, Acute
6
Blast Crisis
6
Neoplasm, Residual
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Neutropenia
3
Neoplasms, Plasma Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Interventions
Doxorubicin
17
Cyclophosphamide
16
Ifosfamide
11
fludarabine
9
Radiotherapy
8
tazemetostat
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Quality of Life
2
Nivolumab
2
Molecular Diagnostic Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
Idarubicin
×
Clear all
NCT00876031
2022-11-08
CWS-2007-HR
University Hospital Tuebingen
Phase 3
Completed
195 enrolled